Hear Larry Schwartz summarize the latest work from the RECIST Working Group. One focuses on clarifying the interpretation of RECIST 1.1, and one provides a summary of current widely accepted alternatives to RECIST in certain specific disease settings.

In “RECIST 1.1 – Update and Clarification: From the RECIST Committee”, the working group has summarized frequently asked questions, focusing mainly on:

• how to select target lesions and what to do with measurable lesions which are not selected for target disease response assessment.
• the definition of stable disease.
• on the role of Fluorodeoxy-glucose (18F) (FDG)-positron emission tomography (PET)/PET-computed tomography in the context of RECIST 1.1.

In “RECIST 1.1 – Standardisation and Disease Specific Adaptations: Perspectives from the RECIST Working Group”, the Working Group summarizes commonly described modifications of RECIST according to the underlying level of evidence using Oxford Centre for Evidence-Based Medicine approach.

In parallel, the working group is also actively working on releasing the results from an extensive analysis of about 50 clinical trials investigating at least one targeted agent.

During the annual RECIST meeting at ASCO, members of the Working Group discussed the final analysis of the aforementioned targeted agents database. A first draft of the recommendations will be prepared over the summer period. After extensive review, this should then lead to a final communication during the course of 2017.

For more information please visit the RECIST for targeted agents page.